

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/47, 31/495, 31/545, 31/71, 47/20	A1	(11) International Publication Number: WO 97/42954 (43) International Publication Date: 20 November 1997 (20.11.97)
(21) International Application Number: PCT/US97/07124 (22) International Filing Date: 5 May 1997 (05.05.97) (30) Priority Data: 08/644,091 10 May 1996 (10.05.96) US (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WATTS, Jeffrey, L. [US/US]; 1608 Whitby Avenue, Portage, MI 49002 (US). WARDLEY, Richard, C. [US/US]; 15216 Marshfield Road, Hickory Corners, MI 49060 (US). STEHLE, Randall, G. [US/US]; 5886 West Q Avenue, Kalamazoo, MI 49009 (US). (74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TOPICAL ADMINISTRATION OF ANTIMICROBIAL AGENTS FOR THE TREATMENT OF SYSTEMIC BACTERIAL DISEASES		
(57) Abstract The present invention provides a method of topically administering antimicrobial agents such as premafloxacin, premafloxacin-like compound, premafloxacin ester, ciprofloxacin, enrofloxacin, cefquinome, cefpodoxime, gentamicin or erythromycin for the treatment of systemic bacterial diseases in mammals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TOPICAL ADMINISTRATION OF ANTIMICROBIAL AGENTS FOR THE TREATMENT OF SYSTEMIC BACTERIAL DISEASES

FIELD OF THE INVENTION

5 The present invention relates to a method of topically administering antimicrobial agents for the treatment of systemic bacterial diseases in mammals.

BACKGROUND OF THE INVENTION

10 It has been generally accepted that intravenous infusion, intramuscular injection, subcutaneous, buccal, oral, and rectal routes are the methods for administration of a wide variety of antimicrobial agents for the treatment of systemic bacterial diseases. Due to lack of systemic level effects with antimicrobial agents administered topically, the topical administration of antimicrobial agents has been limited to the treatment of localized infections of the skin or eyes.

15 However, it is known that the aforementioned non-topical methods of administration for the treatment of systemic bacterial diseases have certain disadvantages. For example, buccal and rectal administration often produce discomfort and aggravation to the mammals that are treated. The intravenous, subcutaneous and intramuscular routes are not only painful, but also must be performed by trained individuals. In addition, there is a risk of needle injury, infection, and other trauma including the emotional trauma inevitably associated with injections. Oral administration, although generally acceptable, may have the disadvantages of poor absorption of the therapeutic agent from the gastrointestinal tract and/or degradation which may be caused by the acidic medium of the stomach, or causes digestive disfunction in ruminants. Furthermore, in the case of treating animals, the aforementioned methods of administration are labor and time consuming. Topical administration of antimicrobial agents would circumvent these problems by allowing a more convenient, non-invasive method for the treatment of systemic bacterial diseases.

20 Thus, it is desirable to have antimicrobial agents that produce systemic effects when they are topically administered for the treatment of systemic diseases.

 It has been unexpectedly discovered, during the investigation of activities of antimicrobial agents by topical administration, that certain antimicrobial quinolones, such as premafloxacin, premafloxacin-like compound, ciprofloxacin, and enrofloxacin, and certain cephalosporin derivatives, such as cefquinome and cefpodoxime, as well as gentamicin and erythromycin, when administered topically

35

using dimethyl sulfoxide and water as a carrier, are effective for the treatment of systemic bacterial infections. It has also been discovered that premafloxacin, premafloxacin-like compound and its esters, when administered topically using propylene glycol and oleyl alcohol or propylene glycol and Azone as a carrier, are effective for the treatment of systemic bacterial infections

INFORMATION DISCLOSURE

Premafloxacin, ciprofloxacin, enrofloxacin, danofloxacin, and their quinolone families are series of new and potent antimicrobial agents with a broad spectrum of antimicrobial activity. These quinolone families are active against a variety of human and veterinary pathogens, including both gram-positive and gram-negative bacteria. Premafloxacin and its esters are disclosed in U.S. Patents 4,665,079 and 5,563,155, issued May 12, 1987 and October 8, 1996 to Warner-Lambert Company. Ciprofloxacin and enrofloxacin are disclosed in U.S. Patent 4,670,444, issued Jun 2, 1987 to Bayer Aktiengesellschaft. Danofloxacin is disclosed in European Patent 215650, issued to Pfizer Inc.

Ceftiofur, cefquinome, and cefpodoxime are derivatives of the family of cephalosporins, which have been recognized as highly active antimicrobial agents. Ceftiofur is disclosed in U.S. Patent 4,464,367, issued August 7, 1984 to Sanofi. Cefpodoxime is disclosed in U.S. Patent 4,486,425, issued December 4, 1984 to Sankyo Company Limited. Cefquinome is a known compound which is disclosed in, among the others, U.S. Patent 4,754,031, European Patent 64,740, and European Patent 74,645.

Gentamicin is a known aminoglycoside antibiotic complex derived from *Micromonospora purpurea*, or *M. Echinospira*. Gentamicin is effective against a wide range of aerobic gram-negative bacilli, especially the *Enterobacteriaceae* and *Pseudomonas*, and some gram-positive bacteria. Gentamicin is disclosed in, inter alia, U.S. Patents 3,091,572 and 3,136,704.

Erythromycin is an intermediate spectrum macrolide antibiotic, produced by *Streptomyces erythreus*, effective against most gram-positive and certain gram-negative bacteria. Erythromycin is disclosed in, among the others, U.S. Patents 2,653,899 and 2,823,203.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a method of treating or preventing systemic bacterial diseases in mammals which comprises topically

administering to such mammal an effective amount of an antimicrobial agent selected from the group consisting of premafloxacin, premafloxacin-like compound, ciprofloxacin, enrofloxacin, cefquinome, cefpodoxime, gentamicin or erythromycin in a DMSO/H₂O carrier.

- 5 In another aspect, the present invention provides a method of treating or preventing systemic bacterial diseases in mammals which comprises topically administering to such mammal an effective amount of premafloxacin, premafloxacin-like compound, or its ester in a PG/OA or a PG/Azone carrier.

10 DETAILED DESCRIPTION OF THE INVENTION


- The present invention resides in the unexpected result that certain antimicrobial quinolones and cephalosporin derivatives as well as gentamicin and erythromycin, when using DMSO/H₂O, as a carrier and when administrated topically, are effective for the treatment of systemic bacterial infections. It is also
15 unexpected that premafloxacin and its esters, when using PG/OA or PG/Azone as a carrier and administrated topically, are effective for the treatment of systemic bacterial infections

- For the purpose of the present invention, systemic bacterial diseases means systemic bacterial infections caused by a variety of human and veterinary
20 pathogens, including both gram-positive and gram-negative bacteria. Such diseases and conditions are well known and readily diagnosed by physicians and veterinarians of ordinary skill.

- The term mammal refers to man and animals of veterinary interest. However, the invention may also be practiced with other vertebrates, and with the
25 lower species comprising the non-vertebrates.


Premafloxacin refers to a compound of formula I or a pharmaceutically acceptable acid addition salt thereof

30



I.

- Premafloxacin ster refers to a compound of formula II or a pharmaceutically
35 acceptable acid addition salt thereof




II

5

wherein R is C₁₋₁₀ straight or branched alkyl such as methyl, ethyl, propyl or butyl, C₁₋₁₀ straight or branched alkenyl, C₁₋₆ cycloalkyl, phenyl, benzyl, naphthyl, or adamantyl.

10 Premafloxacin-like compound refers to a compound of formula III or a pharmaceutically acceptable acid addition salt thereof




III

15

wherein * denotes an asymmetric carbon atom; R₁ is ethyl, cyclopropyl, or 2,4-difluorophenyl; R₂ is hydrogen, C₁₋₄ alkyl or a cation; R₃ is hydrogen, amino, or methyl; R₄ and R₅ are each independently hydrogen or methyl.

20 Ciprofloxacin refers to chemical compound of formula IV or a pharmaceutically acceptable acid addition salt thereof




IV.

25

Enrofloxacin refers to chemical compound of formula V or a pharmaceutically acceptable acid addition salt thereof


30



35


V.

Cefpodoxime refers to a compound of formula VI or a pharmaceutically acceptable acid addition salt thereof.



VI.

10 Cefquinome refers to a compound of formula VII or a pharmaceutically acceptable acid addition salt thereof



VII.

Gentamicin refers to antibiotic complex produced from fermentation of *Micromonospora purpurea* or *M. echinospora* and variants thereof.

20 Erythromycin refers to antibiotic substance produced by a strain of *Streptomyces erythreus*.

Premafloxacin, ciprofloxacin, enrofloxacin, cefquinome, cefpodoxime, gentamicin and erythromycin are commercially available antibiotic agents. Premafloxacin esters and premafloxacin-like compounds can be prepared according to the procedures described in U.S. Patents 4,665,079 and 5,563,155 incorporated
25 herein by reference.

The term DMSO is the abbreviation of dimethyl sulfoxide.

The term PG is the abbreviation of propylene glycol.

The term OA is the abbreviation of oleyl alcohol.

30 Azone refers to hexahydro-1-dodecyl-2H-azepin-2-one.

The term Ivermectin vehicle refers to the carrier and penetrant used to deliver ivermectin, a commonly used topical antiparasitic agent.

Topical administration or application means the direct contact of an antimicrobial formulation with skin such as, for example, by drops, spray, paint, or
35 pour on. The active antimicrobial formulation of the present invention is administrated 1 to 5 times daily until the bacterial infections is treated.

Topical formulations of this invention may be prepared by employing conventional technique to dissolve an antimicrobial agent described above in DMSO and water, in PG and OA, or in PG and Azone. Optionally, the compositions may contain conventional stabilizers and thickening agents.

- 5 For example, an antimicrobial agent is transferred in a DMSO/H₂O carrier, and the mixture is stirred until the solution is clear. When dissolution is complete, the remaining solvents are added to prepare the final concentration of drug and ratio of solvents.

The term DMSO/H₂O carrier refers to the mixture solution of dimethyl sulfoxide and water. MSO and water are in a ratio (DMSO : water) of from 100 : 0
10 to about 10 : 90 by volume to volume (V/V). The use of 100% DMSO by volume achieves the best antimicrobial effect in the present invention, while at least about 10% by volume of DMSO is required in the DMSO and water carrier to have systemic effect.

- 15 In another example, about 95% of PG by volume is mixed with about 5% of OA by volume, or about 95% of PG by volume is mixed with about 5% of Azone by volume. An appropriate amount of a premafloxacin ester is weighed out and transferred to the a graduated mixing flask. The desired carrier is then added to the appropriate volume mark. The flask is sealed and the contents is mixed on a
20 rotator until the solution is clear.

The term PG/OA carrier refers to the mixture solution of propylene glycol and oleyl alcohol. Propylene glycol and oleyl alcohol is in a ratio at least about 80% of propylene glycol by volume. The use of 95% propylene glycol and 5% oleyl alcohol achieves the best antimicrobial effect in the present invention.

- 25 The term PG/Azone carrier refers to the mixture solution of propylene glycol and Azone. Propylene glycol and oleyl alcohol is in a ratio at least about 80% of propylene glycol by volume. The use of 95% propylene glycol and 5% Azone achieves the best antimicrobial effect in the present invention.

The amount of an antimicrobial agent in a formulation may be varied or
30 adjusted widely depending upon the solubility of the particular antimicrobial agent, the potency of the particular antimicrobial agent being used, the severity of the bacterial infection, the particular formulation, and the desired concentration. Generally, the amount of an antimicrobial agent is present in the formulation in a range between about 0.5% to about 90% by weight of the formulation, preferably
35 between ab ut 1% to about 25% by weight of the formulati n.

In therapeutic use for treating systemic bacterial infections in mammals, an

antimicrobial agent is administered topically at a dosage to obtain and maintain a concentration, of which the blood-level of active agent in the mammal being treated is antibacterial effective. Generally, the effective amount of the active agent will be in the range of about 0.1 to about 100 mg/kg, more preferably about 1.0 to about 50 mg/kg of body weight/day. It is understood that the dosages may vary depending upon the requirements of the subject being treated, the severity of the bacterial infection, and the particular antimicrobial agent being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending upon the particular situation.

The present invention achieves the desired results as demonstrated in the mouse systemic protection tests. Mice that had been infected with *Pasteurella haemolytica* are given doses of a formulation of the present invention. The unexpected result of the present invention is realized by their ED₅₀ values. The unexpected results are also demonstrated by the comparison with other routes of administration, with other formulations, and with variety of antimicrobial agents.

In test 1, premafloxacin in an aqueous solution containing 10% DMSO administered topically is compared with premafloxacin administered subcutaneously. Hair is removed from animals in the topically treated group. The ED₅₀ for subcutaneous and topical administrations are 0.12 mg/kg of body weight/day and 3.7 mg/kg of body weight/day, respectively.

In test 2, oral administration of premafloxacin is compared with topical administration of premafloxacin. The topical formulation of premafloxacin is prepared using 100% DMSO and is administered to two groups of mice. One group had hair removed while the hair coat is left undisturbed in the second group. The ED₅₀s for the three groups were 0.6, 0.87, and 3.4 mg/kg for the oral, topical/hair removed, and topical/no hair removed groups, respectively. It appears that while increasing the DMSO from 10% to 100% increased the penetration of premafloxacin, the hair coat decreased the penetration of the antimicrobial agent.

Test 3 illustrates the antimicrobial effect of various formulations on the activity of topically administered premafloxacin. The data demonstrate that premafloxacin in 100% DMSO formulation achieves the highest antimicrobial activity.

Test 4 lists the antimicrobial effects of several quinolones, cephalosporin derivatives as well as gentamicin and erythromycin in 100% DMSO when

administrated topically.

Test 5 illustrates the antimicrobial effect of premafloxacin in a formulation containing PG and OA (95:5 by volume). The result is compared with the antimicrobial effect of premafloxacin in 100% DMSO.

- 5 Test 6 lists antimicrobial effects of premafloxacin esters in a formulation containing PG and Azone (95:5 by volume). The antimicrobial effects of premafloxacin esters are compared with the antimicrobial effect of premafloxacin in 100% DMSO and administered orally.

10

BIOLOGICAL TESTING

1. Bacteria.

- The challenge organism, *Pasteurella haemolytica* UC6531, was originally isolated from a case of bovine pneumonia. The organism was kept frozen at -70 °C in trypticase soy broth containing 10% glycerol on 3 mm glass beads. Prior to use, 15 the organism was subcultured onto a trypticase soy agar plate containing 5% sheep blood and incubated for 18-24 hours at 35 °C under aerobic conditions. A single colony was removed from the blood agar plate, inoculated in 6 ml brain-heart infusion broth (BHIB) and incubated for 6 hours at 35 °C in a 5% CO₂ atmosphere. The organism was then mixed with an equal volume of BHIB containing 2% 20 brewer's yeast which served as the final inoculum.

2. Mouse Systemic Protection Tests

- The *P. haemolytica* mouse systemic protection test was used to evaluate the activity of a new extended spectrum antimicrobial agents by topical administration. 25 For this model, 21-25 day old female CD-1 mice were used. Mice were injected with approximately 100 LD₅₀ doses of the challenge organism intraperitoneal. Antimicrobial agents were administered (0.1 ml) either by subcutaneous injection, orally (subcutaneous and oral administration served as positive controls) or by topical administration. For topical administration, the antimicrobial agent was 30 dissolved in the appropriate solution and placed in a 1 cm² area on the back. All antimicrobial agents were administered within one hour of challenge and at 24 hours intervals for the two following days for a total treatment time of three days. Ten mice were used in each treatment group at each dosage level with five, two-fold serial dilutions of the antimicrobial agent in each determination. The post-challenge 35 effectiveness was calculated based on post-challenge day 6 and was reported as the ED₅₀, the amount of antimicrobial agent (mg/kg body weight/day) required to

protect 50% of infected mice. Antimicrobial agents with lower ED₅₀ values are expected to be more effective. It is generally considered that an agent with a ED₅₀ value less than 10 will display efficacious therapeutic effects in treating systemic bacterial diseases in mammals.

5

TEST 1

Hair is removed from a 1 cm² area of skin on the front shoulder of mice. Premafloxacin in 10% DMSO is administered topically. The result is compared with a group of mice receiving subcutaneous injection of the same antimicrobial agent.

10

Antimicrobial Agent	Administration Route	Formulation	ED ₅₀ (mg/kg/day)
Premafloxacin	Subcutaneous	Aqueous Solution	0.12
Premafloxacin	Topical	10% DMSO	3.7

15

TEST 2

Topical administration of premafloxacin in 100% DMSO in both denuded and normal mice. The results are compared with oral administration of premafloxacin in aqueous solution.

20

Antimicrobial Agent	Administration Route	Formulation	ED ₅₀ (mg/kg/day)
Premafloxacin	Oral	Aqueous Solution	0.6
Premafloxacin	Topical (hair removed)	100% DMSO	0.87
Premafloxacin	Topical (no hair removed)	100% DMSO	3.4

25

TEST 3

Topical administration of the antimicrobial agent in various formulations. Hair was not removed in this test. The results are compared to oral administration of premafloxacin.

5	Antimicrobial Agent	Administration Route	Formulation	ED ₅₀ (mg/kg/day)
	Premafloxacin	Oral	Aqueous Solution	0.6
	Premafloxacin	Topical	100% DMSO	2.2
	Premafloxacin	Topical	Aqueous Solution	>10
10	Premafloxacin	Topical	Propylene Glycol/ Glycerol Formal (60:40)	>10
	Premafloxacin	Topical	PEG 400	>10
	Premafloxacin	Topical	Ivermectin Vehicle	>10

15

TEST 4

Topical administration of various antimicrobial agents in 100% DMSO. Hair was not removed in this test. The results are compared to oral administration of premafloxacin.

20	Antimicrobial Agent	Administration Route	Formulation	ED ₅₀ (mg/kg/day)
	Premafloxacin	Oral	Aqueous Solution	0.9
	Premafloxacin	Topical	100% DMSO	2.6
	Ciprofloxacin	Topical	100% DMSO	0.6
	Enrofloxacin	Topical	100% DMSO	6.7
25	Danofloxacin	Topical	100% DMSO	18.6
	Ceftiofur	Topical	100% DMSO	15.6
	Cefquinome	Topical	100% DMSO	3.6

Cefpodoxime	Topical	100% DMSO	3.1
Gentamicin	Topical	100% DMSO	4.6
Erythromycin	Topical	100% DMSO	3.3
Tilmicosin	Topical	100% DMSO	>50

5

TEST 5

Topical administration of premafloxacin and its esters in formulations containing 95% propylene glycol and 5% oleyl alcohol or 5% Azone. The results are compared with topical administration of premafloxacin in 100% DMSO and oral administration of premafloxacin in aqueous solution.

15

Antimicrobial Agent	Administration Route	Formulation	ED ₅₀ (mg/kg/day)
Premafloxacin	Oral	Aqueous Solution	1.6
Premafloxacin	Topical	100% DMSO	1.7
Premafloxacin	Topical	PG/OA (95:5)	0.9
Premafloxacin butyl ester	Topical	PG/OA (95:5)	0.6
Premafloxacin butyl ester	Topical	PG/Azone (95:5)	0.3
Premafloxacin ethyl ester	Topical	PG/OA (95:5)	0.7
Premafloxacin ethyl ester	Topical	PG/Azone (95:5)	0.4

20

25

CLAIMS

We claim:


1. A use of an antimicrobial agent selected from the group consisting of premafloxacin, premafloxacin-like compound, ciprofloxacin, enrofloxacin, cefquinome,
5 cefpodoxime, gentamicin and erythromycin for the preparation of a medicament to treat or prevent systemic bacterial diseases in mammals which comprises topically administering to such mammal an effective amount of said antimicrobial agent in a DMSO/H₂O carrier wherein said DMSO/H₂O carrier comprises at least 10% of DMSO by volume.
- 10 2. The use according to claim 1 wherein said DMSO/H₂O carrier comprises 60% DMSO by volume.
3. The use according to claim 1 wherein said DMSO/H₂O carrier comprises
15 100% DMSO by volume.
4. The use of claim 1 wherein the antimicrobial agent is premafloxacin.
5. The use of claim 1 wherein the antimicrobial agent is a premafloxacin-like
20 compound.
- 6 The use of claim 1 wherein the antimicrobial agent is ciprofloxacin.
7. The use of claim 1 wherein the antimicrobial agent is enrofloxacin.
- 25 8. The use of claim 1 wherein the antimicrobial agent is cefpodoxime.
9. The use of claim 1 wherein the antimicrobial agent is cefquinome.
- 30 10. The use of claim 1 wherein the antimicrobial agent is gentamicin.
11. The use of claim 1 wherein the antimicrobial agent is erythromycin.
12. A use of an antimicrobial agent selected from the group consisting of
35 premafloxacin, premafloxacin-like compound and premafloxacin ester for the preparation of a medicament to treat or prevent systemic bacterial diseases in

mammals which comprises topically administering to such mammal an effective amount of said antimicrobial agent in a PG/OA carrier.

13. The use of claim 12 wherein said PG/OA carrier comprises about 95% of PG
5 and about 5% OA by volume.

14. The use of claim 12 wherein said antimicrobial agent is premafloxacin or premafloxacin ester.

10 15. The use of claim 12 wherein said premafloxacin ester is a compound of formula II or a pharmaceutically acceptable acid addition salt thereof



II

wherein R is C₁₋₁₀ alkyl, C₁₋₁₀ alkenyl, C₁₋₆ cycloalkyl, phenyl, benzyl, or naphthyl.

20

16. The use of claim 15 wherein R is C₁₋₄ alkyl.

17. The use of claim 15 wherein R is ethyl or butyl.

25 18. A use of an antimicrobial agent selected from the group consisting of premafloxacin, premafloxacin-like compound and premafloxacin ester for the preparation of a medicament to treat or prevent systemic bacterial diseases in mammals which comprises topically administering to such mammal an effective amount of said antimicrobial agent in a PG/Azone carrier.


30

19. The use of claim 18 wherein said PG/Azone carrier comprises about 95% of PG and about 5% Azone by volume.

20. The use of claim 18 wherein said antimicrobial agent is premafloxacin or
35 premafloxacin ester.

21. The use of claim 18 wherein said premafloxacin ester is a compound of formula II or a pharmaceutically acceptable acid addition salt thereof

5



II

10 wherein R is C₁₋₁₀ alkyl, C₁₋₁₀ alkenyl, C₁₋₆ cycloalkyl, phenyl, benzyl, or naphthyl.

22. The use of claim 21 wherein R is C₁₋₄ alkyl.

23. The use of claim 21 wherein R is ethyl or butyl.

15

24. The use of claim 1, 12 or 18 wherein said antimicrobial agent is topically administered in an amount of from about 0.1 to about 100 mg/kg body weight/per day.

20 25. The use of claim 1, 12 or 18 wherein said antimicrobial agent is topically administered in an amount of from about 1.0 to about 50 mg/kg body weight/per day.

INTERNATIONAL SEARCH REPORT

Inter. .onal Application No
PCT/US 97/07124

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/47 A61K31/495 A61K31/545 A61K31/71 A61K47/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 743 727 A (HERSCHLER R) 3 July 1973 see the whole document	1-3,11
X	--- CHEMICAL ABSTRACTS, vol. 87, no. 6, 8 August 1977 Columbus, Ohio, US; abstract no. 44205, B. BAZHDOKOV ET AL.: "DIMETHYL SULFOXIDE AS A CARRIER OF BROAD-SPECTRUM ANTIBIOTICS" XP002040745 see abstract & DERMATOL. VENEROL., vol. 16, no. 1, 1977, SOFIA, pages 33-36, ---	1,10
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

16 September 1997

Date of mailing of the international search report

26.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No

PCT/US 97/07124

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 85 00108 A (DIXON GLEN JACKSON) 17 January 1985 see abstract; claims; examples 3-11 ---	1-11
A	B. IDSON: "PERCUTANEOUS ABSORPTION ENHANCERS" DRUG & COSMETIC, vol. 137, no. 1, 1985, pages 30-32, XP002040744 see the whole document ---	1-25
A	WO 92 09596 A (WARNER LAMBERT CO) 11 June 1992 see abstract see page 54, line 1 - page 67, line 34; claims; examples ---	1-25
A	CHEMICAL ABSTRACTS, vol. 122, no. 4, 23 January 1995 Columbus, Ohio, US; abstract no. 38855, J. MINGWEI ET AL.: "MANUFACTURE OF TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING QUINOLONE DERIVATIVES" XP002040746 see abstract & CN 1 081 103 A (FAMING ZHUANLI SHENQING GONGKAI SHUOMINGSHU) 26 January 1994 -----	18-25
A	EP 0 129 284 A (PROCTER & GAMBLE) 27 December 1984 see abstract see page 2, line 33 - page 4, line 7 see page 8, line 16 - line 33 see page 22, line 26 - page 25, line 23 see page 39, line 3 - line 29; claims; examples -----	12-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Appl. No.

PCT/US 97/07124

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3743727 A	03-07-73	NONE	
WO 8500108 A	17-01-85	US 4507287 A AU 557858 B AU 3068684 A CA 1226220 A DK 77485 A EP 0145779 A	26-03-85 08-01-87 25-01-85 01-09-87 20-02-85 26-06-85
WO 9209596 A	11-06-92	AU 678715 B AU 2334495 A AU 658384 B AU 9057491 A EP 0559774 A IE 62205 B JP 6503565 T NZ 240784 A US 5344940 A US 5461165 A US 5563155 A US 5633264 A US 5258528 A ZA 9109458 A	05-06-97 07-09-95 13-04-95 25-06-92 15-09-93 28-12-94 21-04-94 24-06-97 06-09-94 24-10-95 08-10-96 27-05-97 02-11-93 01-06-93
EP 0129284 A	27-12-84	US 4557934 A AU 560908 B AU 2955784 A CA 1223819 A JP 60036422 A	10-12-85 16-04-87 03-01-85 07-07-87 25-02-85